Nye behandlingsmuligheder ved primær immun trombocytopeni

Sif Gudbrandsdottir; Henrik Frederiksen; Henrik Sverre Birgens; Claus Henrik Nielsen; Ove Juul Nielsen; Jesper Stentoft; Hans Carl Hasselbalch

Nye behandlingsmuligheder ved primær immun trombocytopeni

Translated title of the contribution: [New treatment options for primary immune thrombocytopenia]

Sif Gudbrandsdottir, Henrik Frederiksen, Henrik Sverre Birgens, Claus Henrik Nielsen, Ove Juul Nielsen, Jesper Stentoft, Hans Carl Hasselbalch

1 Citation (Scopus)

Abstract

Primary immune thrombocytopenia (ITP)--formerly known as idiopathic thrombocytopenic purpura--is an autoimmune disorder characterized by immune mediated thrombocytopenia. The aetiology of ITP remains unknown, but studies have shown that multiple immunological mechanisms are involved in the pathogenesis of ITP. This article aims to provide an overview of current treatment options, with particular emphasis on new biological therapies: rituximab, a monoclonal anti-CD20 antibody, and the thrombopoietin receptor agonists romiplostim and eltrombopag.

Translated title of the contribution	[New treatment options for primary immune thrombocytopenia]
Original language	Danish
Journal	Ugeskrift for Laeger
Volume	173
Issue number	4
Pages (from-to)	271-4
Number of pages	4
ISSN	0041-5782
Publication status	Published - 24 Jan 2011

Cite this

@article{9359555eca574dad9aaae3bed79f756a,

title = "Nye behandlingsmuligheder ved prim{\ae}r immun trombocytopeni",

abstract = "Primary immune thrombocytopenia (ITP)--formerly known as idiopathic thrombocytopenic purpura--is an autoimmune disorder characterized by immune mediated thrombocytopenia. The aetiology of ITP remains unknown, but studies have shown that multiple immunological mechanisms are involved in the pathogenesis of ITP. This article aims to provide an overview of current treatment options, with particular emphasis on new biological therapies: rituximab, a monoclonal anti-CD20 antibody, and the thrombopoietin receptor agonists romiplostim and eltrombopag.",

author = "Sif Gudbrandsdottir and Henrik Frederiksen and Birgens, {Henrik Sverre} and Nielsen, {Claus Henrik} and Nielsen, {Ove Juul} and Jesper Stentoft and Hasselbalch, {Hans Carl}",

year = "2011",

month = jan,

day = "24",

language = "Dansk",

volume = "173",

pages = "271--4",

journal = "Ugeskrift for Laeger",

issn = "0041-5782",

publisher = "Almindelige Danske Laegeforening",

number = "4",

}

TY - JOUR

T1 - Nye behandlingsmuligheder ved primær immun trombocytopeni

AU - Gudbrandsdottir, Sif

AU - Frederiksen, Henrik

AU - Birgens, Henrik Sverre

AU - Nielsen, Claus Henrik

AU - Nielsen, Ove Juul

AU - Stentoft, Jesper

AU - Hasselbalch, Hans Carl

PY - 2011/1/24

Y1 - 2011/1/24

N2 - Primary immune thrombocytopenia (ITP)--formerly known as idiopathic thrombocytopenic purpura--is an autoimmune disorder characterized by immune mediated thrombocytopenia. The aetiology of ITP remains unknown, but studies have shown that multiple immunological mechanisms are involved in the pathogenesis of ITP. This article aims to provide an overview of current treatment options, with particular emphasis on new biological therapies: rituximab, a monoclonal anti-CD20 antibody, and the thrombopoietin receptor agonists romiplostim and eltrombopag.

AB - Primary immune thrombocytopenia (ITP)--formerly known as idiopathic thrombocytopenic purpura--is an autoimmune disorder characterized by immune mediated thrombocytopenia. The aetiology of ITP remains unknown, but studies have shown that multiple immunological mechanisms are involved in the pathogenesis of ITP. This article aims to provide an overview of current treatment options, with particular emphasis on new biological therapies: rituximab, a monoclonal anti-CD20 antibody, and the thrombopoietin receptor agonists romiplostim and eltrombopag.

M3 - Tidsskriftartikel

SN - 0041-5782

VL - 173

SP - 271

EP - 274

JO - Ugeskrift for Laeger

JF - Ugeskrift for Laeger

IS - 4

ER -

Nye behandlingsmuligheder ved primær immun trombocytopeni

Abstract

Fingerprint

Cite this